KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for Royalty Pharma (RPRX) over the last 4 years, with Dec 2024 value amounting to $12.1 million.

  • Royalty Pharma's Other Non-Current Liabilities rose 8913.23% to $502.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $502.9 million, marking a year-over-year increase of 8913.23%. This contributed to the annual value of $12.1 million for FY2024, which is 1242.22% up from last year.
  • Royalty Pharma's Other Non-Current Liabilities amounted to $12.1 million in FY2024, which was up 1,242.22% from $900,000 recorded in FY2023.
  • Royalty Pharma's 5-year Other Non-Current Liabilities high stood at $12.1 million for FY2024, and its period low was $900,000 during FY2023.
  • Its 3-year average for Other Non-Current Liabilities is $5.2 million, with a median of $2.5 million in 2022.
  • Per our database at Business Quant, Royalty Pharma's Other Non-Current Liabilities tumbled by 64.00% in 2023 and then soared by 1,242.22% in 2024.
  • Royalty Pharma's Other Non-Current Liabilities (Yearly) stood at $2.5 million in 2022, then plummeted by 64.00% to $900,000 in 2023, then soared by 1,242.22% to $12.1 million in 2024.